Pavan Bhamidipati, MBBS, MD

Author Insights
Cost-Effective Alternative Identified for Autologous Stem Cell Mobilization in Multiple Myeloma
08/14/2017
In a randomized, open-label study, we discovered that tbo-filgrastim (Granix) can be used in the place of filgrastim (Neupogen) for autologous stem cell mobilization for multiple myeloma and non-Hodgkin’s lymphoma...
In a randomized, open-label study, we discovered that tbo-filgrastim (Granix) can be used in the place of filgrastim (Neupogen) for autologous stem cell mobilization for multiple myeloma and non-Hodgkin’s lymphoma...
In a...
08/14/2017
Journal of Clinical Pathways
Guest Blog
Cost-Effective Alternative Identified for Autologous Stem Cell Mobilization in Type of Lymphoma
08/14/2017
In a randomized, open-label study, we discovered that tbo-filgrastim can be used in the place of filgrastim for autologous stem cell mobilization for MM and non-Hodgkin’s lymphoma with no significant differences in efficacy or toxicity.
In a randomized, open-label study, we discovered that tbo-filgrastim can be used in the place of filgrastim for autologous stem cell mobilization for MM and non-Hodgkin’s lymphoma with no significant differences in efficacy or toxicity.
In a randomized, open-label...
08/14/2017
Journal of Clinical Pathways

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use